A series of studies and trials conducted in chronic lymphocytic leukemia (CLL) suggest that an increasing proportion of patients are surviving without disease progression for extended periods. The durable responses, including undetectable minimal residual disease (uMRD) status, have been impressive. At the 2021 meeting of the American Society of Clinical Oncology (ASCO), new data from the CAPTIVATE trial were the latest to suggest new therapies are altering the prognosis of CLL.
The CAPTIVATE